•  
  •  
 

Subject Area

Ophthalmology

Article Type

Original Study

Abstract

Objective The aim of this study was to demonstrate the occurrence of vitreoretinal interface changes in patients with macular edema secondary to branch retinal vein occlusion (BRVO) and diabetic macular edema (DME) after intravitreal injection (IVI) of aflibercept (anti-vascular endothelial growth factor). Background IVI of aflibercept is an effective treatment for macular edema (ME) secondary to BRVO and DME. Patients and methods This prospective comparative case series study was carried out on 50 eyes of 30 patients coming to the Ophthalmology Department of Menoufia University Hospitals. Patients included had ME secondary to BRVO and DME. Patients were randomly enrolled into two groups. Group A included 16 eyes which had ME secondary to BRVO. Group B included 34 eyes which had ME secondary to DME. Results The results revealed that there was no significant difference between the studied groups regarding postoperative visual outcome and central macular thickness. However, there was a significant increase in epiretinal membrane complication in BRVO group than DME group postoperatively. Conclusion After IVI of aflibercept for ME, there was a significant improvement in visual acuity, all over the period of follow-up. Moreover, the optical coherence tomography improved significantly. The rate of complications was higher in the BRVO group than the DM group. The presence of vitreoretinal interface abnormalities affected the effectiveness of anti-vascular endothelial growth factor and final visual outcome.

Download

Share

COinS